VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

Rhea-AI Summary

VolitionRx Limited (NYSE: VNRX) has announced a breakthrough in veterinary diagnostics with the successful detection of nucleosomes in cats, published in BMC Veterinary Research. This marks the first-ever detection of nucleosomes in felines, following previous successful applications in dogs and humans. The company's Nu.Q® technology shows promise for cancer screening in cats, particularly targeting feline lymphoma, the most common cancer in cats. The market opportunity is significant, with over 60 million cats in the U.S., of which 25% are seniors suitable for annual screening. The study confirms that H3.1 nucleosomes can be quantified from feline blood samples and establishes optimal collection protocols using EDTA tubes. Clinical trials for feline lymphoma detection are currently underway.

Positive

• First successful detection of nucleosomes in cats, expanding Nu.Q® technology to a third species
• Large market opportunity with over 60 million cats in the U.S., 25% being potential screening candidates
• Clinical study for feline lymphoma detection already in progress
• Established successful collection and processing protocol for feline testing

Negative

• None.

Clinical Paper Published in BMC Veterinary Research

HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer.

Frederic Wuilque, Vice President, Global Products, said:

"This is an essential step in the development of Nu.Q^® products for cats, our third species. This opens up the potential for cancer screening and monitoring in cats, representing a significant annual commercial opportunity for Volition. There are more than 60 million cats in the U.S. alone, 25% of which are "senior" cats and therefore suitable for an annual check¹.

"This important study confirms that H3.1 nucleosomes can be successfully quantified from blood obtained from healthy cats and presents data regarding an optimal collection and processing protocol. Additionally, it supports the use of EDTA tubes when collecting samples for nucleosome testing in cats. 

"Our first target product is for feline lymphoma, the most common cause of cancer in cats². We are delighted to have completed the pre-analytics work for feline and confirm that the enrolment for patients for our clinical study for the detection of feline lymphoma has been underway for several months. We look forward to presenting the findings of our Nu.Q^® Vet assay in this much needed area  upon study completion."

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

^1. Data on File. Volition Total Accessible Market Model.

^2. Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.

View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-successful-detection-of-nucleosomes-in-cats-302458975.html

SOURCE VolitionRx Limited

FAQ

What is the significance of VNRX's nucleosome detection in cats?

This is the first-ever detection of nucleosomes in cats, enabling potential cancer screening and monitoring, particularly for feline lymphoma. This expands VolitionRx's Nu.Q® technology to a third species after humans and dogs.

What is the market opportunity for VNRX's feline cancer screening?

There are over 60 million cats in the U.S., with 25% being senior cats suitable for annual screening, representing a significant commercial opportunity for VolitionRx.

What type of cancer is VNRX's Nu.Q® Vet targeting in cats?

VolitionRx is primarily targeting feline lymphoma, which is the most common type of cancer in cats.

What is the current status of VNRX's feline cancer detection study?

VolitionRx has completed the pre-analytics work and patient enrollment for their clinical study on feline lymphoma detection has been ongoing for several months.

What type of sample collection method is recommended for VNRX's nucleosome testing in cats?

The study supports the use of EDTA tubes for collecting blood samples for nucleosome testing in cats.